(ADMA) ADMA Biologics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.799m USD | Total Return: -60.8% in 12m
Avg Turnover: 28.1M
Qual. Beats: -1
Rev. Trend: 96.9%
Qual. Beats: -1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
ADMA Biologics is a vertically integrated biopharmaceutical company specializing in the development and commercialization of plasma-derived biologics. The company manages the full lifecycle of its products, from the operation of source plasma collection centers to the manufacturing and distribution of specialty treatments for primary humoral immunodeficiency and infectious diseases.
The company’s commercial portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies, and Nabi-HB for Hepatitis B exposure. This business model relies on a complex fractionating process to extract specific antibodies from human plasma, a sector characterized by high barriers to entry and rigorous regulatory oversight due to the biological nature of the raw materials.
ADMA distributes its therapeutics through a network of wholesalers, specialty pharmacies, and independent distributors. Investors may find additional performance metrics and peer comparisons by exploring ValueRay. Headquartered in New Jersey, the firm continues to develop a pipeline focused on preventing Streptococcus pneumoniae infections using its proprietary plasma-derived platform.
- ASCENIV adoption and utilization rates drive high-margin revenue growth
- Vertical integration of plasma collection centers stabilizes raw material costs
- FDA regulatory compliance at manufacturing facilities ensures uninterrupted product supply
- Expansion of intravenous immune globulin market share increases total revenue
- Operational leverage improvement accelerates transition toward sustained net profitability
| Net Income: 165.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.53 > 1.0 |
| NWC/Revenue: 85.83% < 20% (prev 64.94%; Δ 20.89% < -1%) |
| CFO/TA 0.19 > 3% & CFO 128.3m > Net Income 165.4m |
| Net Debt (73.8m) to EBITDA (212.6m): 0.35 < 3 |
| Current Ratio: 6.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.0m) vs 12m ago -1.93% < -2% |
| Gross Margin: 61.27% > 18% (prev 52.58%; Δ 8.70% > 0.5%) |
| Asset Turnover: 86.73% > 50% (prev 89.97%; Δ -3.24% > 0%) |
| Interest Coverage Ratio: 28.28 > 6 (EBIT TTM 204.6m / Interest Expense TTM 7.24m) |
| A: 0.66 (Total Current Assets 511.2m - Total Current Liabilities 73.5m) / Total Assets 665.2m |
| B: -0.17 (Retained Earnings -116.3m / Total Assets 665.2m) |
| C: 0.35 (EBIT TTM 204.6m / Avg Total Assets 587.9m) |
| D: 1.42 (Book Value of Equity 390.3m / Total Liabilities 274.9m) |
| Altman-Z'' = 7.58 = AAA |
| DSRI: 1.23 (Receivables 135.9m/99.4m, Revenue 509.9m/459.4m) |
| GMI: 0.86 (GM 52.58% / 61.27%) |
| AQI: 0.68 (AQ_t 0.12 / AQ_t-1 0.18) |
| SGI: 1.11 (Revenue 509.9m / 459.4m) |
| TATA: 0.06 (NI 165.4m - CFO 128.3m) / TA 665.2m) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of June 06, 2026, the stock is trading at USD 7.97 with a total of 2,349,489 shares traded.
Over the past week, the price has changed by +0.63%,
over one month by -22.60%,
over three months by -51.75% and
over the past year by -60.75%.
ADMA Biologics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ADMA.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.8 | 110.2% |
P/E Trailing = 11.4118
P/E Forward = 9.5147
P/S = 3.5275
P/B = 4.691
Revenue TTM = 509.9m USD
EBIT TTM = 204.6m USD
EBITDA TTM = 212.6m USD
Long Term Debt = 193.6m USD (from longTermDebt, last quarter)
Short Term Debt = 4.46m USD (from shortTermDebt, last quarter)
Debt = 211.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.54m
Net Debt = 73.8m USD (calculated: Debt 211.9m - CCE 138.2m)
Enterprise Value = 1.87b USD (1.80b + Debt 211.9m - CCE 138.2m)
Interest Coverage Ratio = 28.28 (Ebit TTM 204.6m / Interest Expense TTM 7.24m)
EV/FCF = 17.35x (Enterprise Value 1.87b / FCF TTM 107.9m)
FCF Yield = 5.76% (FCF TTM 107.9m / Enterprise Value 1.87b)
FCF Margin = 21.16% (FCF TTM 107.9m / Revenue TTM 509.9m)
Net Margin = 32.43% (Net Income TTM 165.4m / Revenue TTM 509.9m)
Gross Margin = 61.27% ((Revenue TTM 509.9m - Cost of Revenue TTM 197.4m) / Revenue TTM)
Gross Margin QoQ = 70.53% (prev 63.82%)
Tobins Q-Ratio = 2.81 (Enterprise Value 1.87b / Total Assets 665.2m)
Interest Expense / Debt = 3.41% (Interest Expense 7.24m / Debt 211.9m)
Taxrate = 19.86% (41.0m / 206.3m)
NOPAT = 164.0m (EBIT 204.6m * (1 - 19.86%))
Current Ratio = 6.95 (Total Current Assets 511.2m / Total Current Liabilities 73.5m)
Debt / Equity = 0.54 (Debt 211.9m / totalStockholderEquity, last quarter 390.3m)
Debt / EBITDA = 0.35 (Net Debt 73.8m / EBITDA 212.6m)
Debt / FCF = 0.68 (Net Debt 73.8m / FCF TTM 107.9m)
Total Stockholder Equity = 424.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.13% (Net Income 165.4m / Total Assets 665.2m)
RoE = 38.97% (Net Income TTM 165.4m / Total Stockholder Equity 424.3m)
RoCE = 33.12% (EBIT 204.6m / Capital Employed (Equity 424.3m + L.T.Debt 193.6m))
RoIC = 28.74% (NOPAT 164.0m / Invested Capital 570.6m)
WACC = 9.19% (E(1.80b)/V(2.01b) * Re(9.95%) + D(211.9m)/V(2.01b) * Rd(3.41%) * (1-Tc(0.20)))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 20.0 | Cagr: 2.71%
[DCF] Terminal Value 75.30% ; FCFF base≈101.0m ; Y1≈115.8m ; Y5≈170.4m
[DCF] Fair Price = 9.32 (EV 2.23b - Net Debt 73.8m = Equity 2.16b / Shares 231.8m; r=9.19% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.12 | # QB: -1
Revenue Correlation: 96.93 | Revenue CAGR: 41.86% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.18 | Chg30d=-28.00% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.21 | Chg30d=-25.00% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.83 | Chg30d=-20.19% | Revisions=-20% | GrowthEPS=+26.4% | GrowthRev=+11.7%
EPS next Year (2027-12-31): EPS=1.06 | Chg30d=-14.78% | Revisions=-20% | GrowthEPS=+27.3% | GrowthRev=+27.4%
[Analyst] Revisions Ratio: -20%